These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9759192)

  • 1. [What uses for the acellular pertussis vaccine?].
    Grimprel E; Bégué P
    Arch Pediatr; 1998 May; 5(5):557-60. PubMed ID: 9759192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age.
    Langue J; Matisse N; Pacoret P; Undreiner F; Boisnard F; Soubeyrand B;
    Vaccine; 2004 Mar; 22(11-12):1406-14. PubMed ID: 15063563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acellular pertussis vaccines: new preparation. Better tolerated but less active?
    Prescrire Int; 2000 Feb; 9(45):204-7. PubMed ID: 11503797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New acellular pertussis-containing paediatric combined vaccines.
    Pines E; Barrand M; Fabre P; Salomon H; Blondeau C; Wood SC; Hoffenbach A
    Vaccine; 1999 Mar; 17(13-14):1650-6. PubMed ID: 10194818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster.
    Mallet E; Matisse N; Mathieu N; Langue J; Boisnard F; Soubeyrand B;
    Vaccine; 2004 Mar; 22(11-12):1415-22. PubMed ID: 15063564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
    Dhillon S
    BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tolerance of acellular pertussis vaccine booster injection in 15-20-month-old children].
    Mallet E; Puyt A; Arson S; Surbled V
    Arch Pediatr; 2000 Apr; 7(4):410-4. PubMed ID: 10793931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles.
    van der Lee S; Hendrikx LH; Sanders EAM; Berbers GAM; Buisman AM
    Front Immunol; 2018; 9():51. PubMed ID: 29416544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.
    Thierry-Carstensen B; Dalby T; Stevner MA; Robbins JB; Schneerson R; Trollfors B
    Vaccine; 2013 Oct; 31(45):5178-91. PubMed ID: 23994021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined acellular pertussis vaccines: new indication. No tangible benefit in primary vaccination.
    Prescrire Int; 2002 Jun; 11(59):73-5. PubMed ID: 12068840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
    Halperin SA; Scheifele D; Barreto L; Pim C; Guasparini R; Medd L; Meekison W; Eastwood BJ
    Pediatr Infect Dis J; 1999 Sep; 18(9):772-9. PubMed ID: 10493336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccines and effect of a booster dose.
    Vermeulen F; Dirix V; Verscheure V; Damis E; Vermeylen D; Locht C; Mascart F
    Vaccine; 2013 Apr; 31(15):1981-6. PubMed ID: 23429006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age.
    Halperin SA; Mills E; Barreto L; Pim C; Eastwood BJ
    Pediatr Infect Dis J; 1995 Sep; 14(9):792-7. PubMed ID: 8559630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
    Zepp F; Knuf M; Heininger U; Jahn K; Collard A; Habermehl P; Schuerman L; Sänger R
    Vaccine; 2004 Jun; 22(17-18):2226-33. PubMed ID: 15149781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants.
    Blennow M; Granström M
    Pediatrics; 1989 Jul; 84(1):62-7. PubMed ID: 2544850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of whole cell pertussis immunisation: collected data on a vaccine produced in France.
    Fletcher MA; Saliou P; Ethevenaux C; Plotkin SA
    Public Health; 2001 Mar; 115(2):119-29. PubMed ID: 11406777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pertussis vaccination with acellular vaccines. Tolerance--effectiveness--current vaccination recommendations].
    Liese JG; Stojanov S; Belohradsky BH
    Fortschr Med; 1997 Aug; 115(24):22-7. PubMed ID: 9410815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.